RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease

Stock Information for Redhill Biopharma Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Redhill Biopharma Ltd.

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
RedHill Biopharma Announces $8 Million Registered Direct Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.